The function of EpCAM-AsiCs in the process of cancer immunity was evaluated in genetically engineered mouse breast cancer models, which indicated that Upf2, Parp1, Cd47, and Mcl1 knockdown by EpCAM-AsiCs obviously inhibited tumor progression and promoted tumor-infiltrating immune cell functions. Here, EPCAM is linked to breast carcinoma.